Patent ID: 8916588

Claim:
A method of treating a condition in a subject with a disorder or condition responsive to the administration of a methylphenidate, comprising orally administering to the subject an effective amount of methylphenidate or a pharmaceutical salt thereof in a formulation comprising a core comprising methylphenidate or a pharmaceutical salt thereof and at least one pharmaceutically acceptable excipient; a sustained release layer enclosing the core and a delayed release layer enclosing the sustained release layer, wherein when the formulation is administered to said subject it provides: (i) a lag period of at least 5 hours during which the plasma concentration of methylphenidate or a pharmaceutical salt thereof is less than 10% of the maximum concentration (C max ); (ii) a plasma area under the curve at 10 hours (AUC 0-10 ) after administration of less than about 7% of AUC 0-48 ; and (iii) wherein the time to C max (T max ) is between 12 and 19 hours after administration.